OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
Mergers & Acquisitions
Mergers & Acquisitions Summary
Each week, Viridian publishes insights and analysis on completed M&A transactions in the prior week. Our analysis includes:
-
- M&A Market Commentary
- Public and Private Companies
- Buyers & Sellers
- YTD M&A Analysis
- M&A by Industry Sector
- Deal Structure and Valuation Analysis
- Pending Deal Risk Arb Analysis
- Valuation Gap Analysis
Quick Links
Transaction Activities
Week ended 07/21/2023
- Three M&A transactions closed this week for disclosed transaction value of $2.81M compared to two transactions for $0.75M in the prior year.
YTD Activities
- Seventy-one transactions totaling $1.18B have closed YTD, compared to one hundred and sixteen transactions for $09B last year.
- The 2023 YTD average transaction size of $16.64M is the lowest in recent years.
Pending Risk Deal Arb Analysis
-
- The Cresco/Columbia deal spread declined to 99.0% on 7/21/23. Although both parties said they were “working amicably with respect to next steps,” the arb spread indicates the market does not believe this deal will close as presently structured. The spread may also relate to the relative credit qualities of the two companies. Columbia Care “needs” the deal more than Columbia does, although both companies need the asset sale proceeds to reduce debt to long-term sustainable levels of under 3x EBITDA.
Valuation Gap Analysis
- The valuation gap narrowed by 37bp to 4.22 on 7/21/23, still close to the highest the measure has been since early 2022. The valuation gap is the difference between the EV/NTM EBITDA multiple for the largest MSOs and the multiple for the less than $300M market cap group, which are their primary targets.
- This measure has been a significant driver of M&A activity since a larger gap creates an opportunity for more accretive transactions. The gap tends to increase in improving markets while declining in retreating markets to the greater trading liquidity of the larger companies. We believe the current gap is still understated by the massive illiquidity of cannabis stocks which may not be accurate indicators of the prices at which the entire companies would trade.
Please login to your account to view data charts.
